Medpace Holdings, Inc.MEDP

時価総額

$166.3億

PER

臨床開発受託（CRO）の世界的最大手。フェーズI–IVのフルサービスと中央検査・バイオ分析ラボを展開。2024年に株式買戻しで527,160株、1.742億ドルの実施。約5,900人で北米・欧州・アジア44カ国展開。

	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net income	13	39	73	100	145	182	245	283	404
Depreciation	7	9	9	8	12	16	19	24	28
Amortization	51	38	30	15	8	5	3	2	1
Stock-based compensation expense	10	4	6	21	14	14	21	21	26
Operating Lease, Right-of-Use Asset, Periodic Reduction	-	-	-	-	-	-	-	-	23
Deferred income tax benefit	-9	3	4	10	1	-37	-23	-25	-27
Other	1	1	-2	-2	0	-1	2	-3	4
Accounts receivable and unbilled, net	14	3	27	21	6	25	67	48	-2
Prepaid expenses and other current assets	4	4	1	7	4	9	10	-3	12
Accounts payable	1	5	1	5	-3	2	6	1	-3
Accrued expenses	5	-1	29	22	24	26	52	82	17
Advanced billings	-	-	36	45	63	89	118	97	151
Lease liabilities	-	-	-	-	-	-	-	-19	-21
Other assets and liabilities, net	1	-3	-2	-2	-2	1	-22	10	-24
Net cash provided by operating activities	-	-	157	202	259	263	388	433	609
Property and equipment expenditures	14	12	16	18	31	28	37	37	37
Other	-0	-0	1	1	-0	3	2	-2	-8
Net cash used in investing activities	-	-	-17	-19	-31	-31	-39	-35	-28
Proceeds from stock option exercises	1	2	2	7	16	18	22	11	16
Repurchases of common stock	-	156	-	-	98	62	848	144	170
Proceeds from revolving loan	-	100	-	-	-	-	324	105	-
Payments on revolving loan	-	30	70	-	-	-	274	155	-
Net cash used in financing activities	-	-	-142	-74	-82	-44	-776	-183	-154
EFFECT OF EXCHANGE RATES ON CASH, CASH EQUIVALENTS, AND RESTRICTED CASH	-	2	-1	-0	1	-4	-7	1	-3
INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH	-	-11	-3	109	146	184	-433	217	424
Income Taxes Paid, Net	18	17	23	13	23	56	50	76	84
Cash paid during the period for interest	-	-	8	1	0	0	3	3	0
Acquisition of property and equipment—non-cash	2	1	2	3	19	6	8	5	5
Noncash or part noncash, share repurchases	-	-	-	-	-	-	-	-	4